How to buy Vaxart shares

Vaxart, Inc is a biotechnology business with stocks listed in the US. Vaxart shares (VXRT) are listed on the NASDAQ and all prices are listed in US Dollars. Here's how to invest if you're based in Australia.

How to buy shares in Vaxart

1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
3. Search for Vaxart. Find the share by name or ticker symbol: VXRT. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Vaxart reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Vaxart, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Vaxart. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

US stocks

eToro Share Trading (US stocks)

Finder Award

Our top pick for

Cheap broker fees

IG Share Trading

Finder Award

Our top pick for

Long-term investing

CMC Markets Stockbroking

Finder Award

Vaxart share price

Compare share trading platforms to buy stock

Sort by:

Name	Product	Standard brokerage for US shares	Inactivity fee	Currency conversion fee	Markets
eToro Share Trading (US stocks) Finder Award		US$0	US$10 per month if there’s been no login for 12 months	0.50%	US shares	Zero brokerage share trading on US stocks with trades as low as $50. Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.	Go to site More Info	Compare	loading Fetching your data...
IG Share Trading Finder Award		US$0	$50 per quarter if you make fewer than three trades in that period	0.70%	ASX shares, Global shares	$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares. Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.	Go to site More Info	Compare	loading Fetching your data...
CMC Markets Stockbroking Finder Award		US$0	No	0.60%	ASX shares, Global shares, mFunds, ETFs	$0 brokerage on global shares including US, UK and Japan markets. Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.	Go to site More Info	Compare	loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

Is it a good time to buy Vaxart stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Shorting Vaxart shares

There are currently 23.9 million Vaxart shares held short by investors – that's known as Vaxart's "short interest". This figure is 7.4% down from 25.8 million last month.

There are a few different ways that this level of interest in shorting Vaxart shares can be evaluated.

Vaxart's "short interest ratio" (SIR)

Vaxart's "short interest ratio" (SIR) is the quantity of Vaxart shares currently shorted divided by the average quantity of Vaxart shares traded daily (recently around 5.5 million). Vaxart's SIR currently stands at 4.36. In other words for every 100,000 Vaxart shares traded daily on the market, roughly 4360 shares are currently held short.

However Vaxart's short interest can also be evaluated against the total number of Vaxart shares, or, against the total number of tradable Vaxart shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vaxart's short interest could be expressed as 0.2% of the outstanding shares (for every 100,000 Vaxart shares in existence, roughly 200 shares are currently held short) or 0.2601% of the tradable shares (for every 100,000 tradable Vaxart shares, roughly 260 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vaxart.

Find out more about how you can short Vaxart stock.

Vaxart share dividends

We're not expecting Vaxart to pay a dividend over the next 12 months.

Have Vaxart's shares ever split?

Vaxart's shares were split on a 1:11 basis on 13 February 2018. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vaxart shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for Vaxart shares which in turn could have impacted Vaxart's share price.

Vaxart share price volatility

Over the last 12 months, Vaxart's shares have ranged in value from as little as US$2.02 up to US$17.15. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vaxart's is 0.1009. This would suggest that Vaxart's shares are less volatile than average (for this exchange).

Vaxart overview

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.

Frequently asked questions

• What percentage of Vaxart is owned by insiders or institutions?

  Currently 0.603% of Vaxart shares are held by insiders and 34.313% by institutions.

• When does the fiscal year end for Vaxart?

  Vaxart's fiscal year ends in December.

• Where is Vaxart based?

  Vaxart's address is: 170 Harbor Way, South San Francisco, CA, United States, 94080

• What is Vaxart's ISIN number?

  Vaxart's international securities identification number is: US92243A2006

• What is Vaxart's CUSIP number?

  Vaxart's Committee on Uniform Securities Identification Procedures number is: 053761102